Re: USA ZHCLF investors
in response to
by
posted on
Oct 30, 2022 05:12PM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
Correct but on the flip side, the RPSs would theoretically be factored into a sale price for RVX or any part thereof reducing that sale price. The buyer has to pay those royalties out of their profit or negotiate a price to buy back the RPSs.
True, but given that I sold all my RVX shares and put a sizeable portion of the proceeds into ZHCLF shares, I'm unable to fully appreciate this flip-side problem.